Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

With Serial Entrepreneur At Its Helm, Arrakis Raises $38m To Target RNA With Small Molecules

Executive Summary

Serial entrepreneur Michael Gilman has taken the helm of another start-up; after selling Padlock to Bristol-Myers and Stromedix to Biogen, his new company Arrakis has raised a $38m Series A round with big biopharma backing.

Advertisement

Related Content

Arrakis Pivots From Platform To Pipeline With $75m For RNA-Targeting Small Molecules
Start-Up Obsidian Gets $49.5m To Determine How And When To Activate CAR-T Cells
Finance Watch: Canaan Closes New VC Fund; CARB-X Backs More Antibiotics
Finance Watch: Cash Flows Into Public Biopharmas, Including IPOs; Atlas Raises $350m VC Fund
Cardior Exploring MicroRNAs As Heart Failure Target
Henri Termeer Dies Aged 71
Pfizer Jumps At The Chance To Apply Bind’s Technology To Immuno-Oncology
Value Unlocked: BMS Buying Padlock For Up To $600m
'Welcome home': Stromedix buy brings fibrosis drug back to Biogen
Celgene to acquire Avila Therapeutics for $350m plus $575m in milestones

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC098299

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel